DUBLIN, Nov. 19,
2024 /PRNewswire/ -- Jazz Pharmaceuticals plc
(Nasdaq: JAZZ) today announced that the Company will participate in
Citi's 2024 Global Healthcare Conference. Company management will
participate in a fireside chat on Tuesday,
December 3, 2024, at 7:15 a.m.
PT / 10:15 a.m. ET /
3:15 p.m. GMT.
An audio webcast of the fireside chat will be available via the
Investors section of the Jazz Pharmaceuticals website
at https://investor.jazzpharma.com/investors/events-presentations.
A replay of the webcast will be archived on the website for 30
days.
About Jazz Pharmaceuticals
Jazz
Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company
whose purpose is to innovate to transform the lives of patients and
their families. We are dedicated to developing life-changing
medicines for people with serious diseases — often with limited or
no therapeutic options. We have a diverse portfolio of marketed
medicines, including leading therapies for sleep disorders and
epilepsy, and a growing portfolio of cancer treatments. Our
patient-focused and science-driven approach powers pioneering
research and development advancements across our robust pipeline of
innovative therapeutics in oncology and neuroscience. Jazz is
headquartered in Dublin, Ireland
with research and development laboratories, manufacturing
facilities and employees in multiple countries committed to serving
patients worldwide. Please
visit www.jazzpharmaceuticals.com for more
information.
Contacts:
Investors:
Andrea N.
Flynn, Ph.D.
Vice President, Head, Investor Relations
Jazz Pharmaceuticals plc
InvestorInfo@jazzpharma.com
Ireland +353 1 634 3211
U.S. +1 650 496 2717
Media:
Kristin
Bhavnani
Head of Global Corporate Communications
Jazz Pharmaceuticals plc
CorporateAffairsMediaInfo@jazzpharma.com
Ireland +353 1 637 2141
U.S. +1 215 867 4948
Logo -
https://mma.prnewswire.com/media/272253/Jazz_Pharmaceuticals_New_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/jazz-pharmaceuticals-to-participate-in-citis-2024-global-healthcare-conference-302310548.html